| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7189761 | ABBVIE | Nitric oxide donor composition and method for treatment of anal disorders |
May, 2014
(9 years ago) | |
Rectiv is owned by Abbvie.
Rectiv contains Nitroglycerin.
Rectiv has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Rectiv are:
- US7189761
Rectiv was authorised for market use on 21 June, 2011.
Rectiv is available in ointment;intra-anal dosage forms.
Rectiv can be used as rectiv is a nitrate vasodilator indicated for the treatment of moderate to severe pain associated with chronic anal fissure.
The generics of Rectiv are possible to be released after 21 June, 2014.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2014 |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 21 June, 2011
Treatment: Rectiv is a nitrate vasodilator indicated for the treatment of moderate to severe pain associated with chronic anal fissure
Dosage: OINTMENT;INTRA-ANAL
RECTIV family patents
